DEXCOM INC (DXCM) — SEC Filings

Latest SEC filings for DEXCOM INC (DXCM), explained in plain English.

Sentiment Overview: 2 bullish, 26 neutral

Recent Filings (28)

• Dexcom Inc. Files 8-K on Director Changes and Compensation — 8-K · 2025-12-22T00:00:00.000Z [neutral] Risk: low
  On December 19, 2025, Dexcom, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election
• Dexcom's Q3 Net Income Soars 111% on Strong Revenue Growth — 10-Q · 2025-10-30T00:00:00.000Z [bullish] Risk: medium
  Dexcom Inc. reported robust financial growth for the three and nine months ended September 30, 2025. Revenue increased by 21.6% to $1,209.3 million for the thre
• DexCom Reports Officer Changes and Compensation Details — 8-K · 2025-10-27T00:00:00.000Z [neutral] Risk: medium
  DexCom, Inc. filed an 8-K on October 27, 2025, reporting events on October 24, 2025. The filing pertains to the departure of directors or certain officers, the
• DexCom CFO Departs; Interim Appointed, New Directors Elected — 8-K · 2025-09-16T00:00:00.000Z [neutral] Risk: medium
  DexCom, Inc. announced on September 14, 2025, the departure of its Chief Financial Officer, Parth Desai. The company has appointed Jerrod Hill as the interim CF
• Dexcom's Q2 Revenue Jumps 20% to $1.05B on Strong CGM Demand — 10-Q · 2025-07-30T00:00:00.000Z [bullish] Risk: medium
  Dexcom Inc. reported robust financial performance for the second quarter ended June 30, 2025, with revenue reaching $1.05 billion, marking a significant 20% inc
• DexCom Reports Director/Officer Changes & Compensation — 8-K · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  DexCom, Inc. filed an 8-K on May 13, 2025, reporting events as of May 9, 2025. The filing primarily concerns the departure of directors or certain officers, the
• DexCom Files 8-K Amendment on Officer/Director Changes — 8-K/A · 2025-05-09T00:00:00.000Z [neutral] Risk: medium
  DexCom, Inc. filed an amendment (8-K/A) on May 9, 2025, to its report originally dated March 6, 2025. The amendment pertains to the departure of directors or ce
• Dexcom Adds New Directors, Updates Executive Pay — 8-K · 2025-05-02T00:00:00.000Z [neutral] Risk: low
  On May 1, 2025, Dexcom, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the
• DexCom Inc. Files Q1 2025 10-Q — 10-Q · 2025-05-01T00:00:00.000Z [neutral] Risk: low
  DexCom Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025.
• DexCom Inc. Files 2025 Proxy Statement — DEF 14A · 2025-03-27T00:00:00.000Z [neutral] Risk: low
  DexCom Inc. filed its DEF 14A on March 27, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate gov
• DexCom Reports Change in Certifying Accountant — 8-K · 2025-03-25T00:00:00.000Z [neutral] Risk: low
  DexCom, Inc. filed an 8-K on March 25, 2025, reporting changes in its certifying accountant. The filing indicates that the company's principal accounting firm h
• DexCom CFO Departs; Interim Appointed — 8-K · 2025-03-10T00:00:00.000Z [neutral] Risk: medium
  DexCom, Inc. announced on March 6, 2025, the departure of its Chief Financial Officer, Jereme Ryan, effective March 10, 2025. The company also announced the app
• Dexcom Inc. Updates Product Pipeline and Strategy — 8-K · 2025-03-07T00:00:00.000Z [neutral] Risk: low
  On March 4, 2025, Dexcom, Inc. announced a significant development regarding its Continuous Glucose Monitoring (CGM) systems. The company is providing an update
• Dexcom Inc. Files 2024 10-K — 10-K · 2025-02-18T00:00:00.000Z [neutral] Risk: low
  Dexcom Inc. filed its 2024 10-K on February 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in San Diego, CA, operat
• Dexcom, Inc. Files 8-K with Financial Updates — 8-K · 2025-02-13T00:00:00.000Z [neutral] Risk: low
  On February 13, 2025, Dexcom, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, pr
• DexCom Files 8-K on Financials — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  DexCom, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhi
• Dexcom, Inc. Enters Material Definitive Agreement — 8-K · 2024-12-23T00:00:00.000Z [neutral] Risk: medium
  On December 20, 2024, Dexcom, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, such as the c
• SC 13G/A Filing — SC 13G/A · 2024-12-06T00:00:00.000Z [neutral]
• DexCom Inc. Files Q3 2024 10-Q — 10-Q · 2024-10-24T00:00:00.000Z [neutral] Risk: low
  DexCom Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of 2
• DexCom Inc. Files 2024 Q2 10-Q Report — 10-Q · 2024-07-25T00:00:00.000Z [neutral] Risk: low
  DexCom Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the second quarter of 2024, detailing financial performance and operational up
• Dexcom, Inc. Files 8-K on Security Holder Vote Matters — 8-K · 2024-05-24T00:00:00.000Z [neutral] Risk: low
  On May 22, 2024, Dexcom, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not disclose specific p
• DexCom Inc. Q1 2024 10-Q Filing — 10-Q · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  DexCom Inc. filed its 10-Q for the quarter ending March 31, 2024, reporting on its financial performance. The company's fiscal year ends on December 31st, and t
• DexCom Inc. Executive Compensation Details Revealed — DEF 14A · 2024-04-22T00:00:00.000Z [neutral] Risk: low
  DexCom Inc. filed a DEF 14A on April 22, 2024, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes information on
• Dexcom Reports Material Agreements & Equity Sales — 8-K · 2024-02-15T00:00:00.000Z [neutral] Risk: medium
  DEXCOM, INC. filed an 8-K on February 15, 2024, reporting events that occurred on February 13, 2024. The filing indicates the entry into a material definitive a
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• DEXCOM 2023 10-K Filed: Financials & Operations Detailed — 10-K · 2024-02-08T00:00:00.000Z [neutral] Risk: medium
  Dexcom Inc. filed its 10-K on February 8, 2024, for the fiscal year ending December 31, 2023. This filing provides a comprehensive overview of the company's fin
• BlackRock Amends Dexcom Stake: Passive Investment Update — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating a change in its ownership stake in Dexcom Inc. as of December 31, 2023. This filing, Am
• Dexcom Files Routine 8-K, Confirms Nasdaq Listing — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  This 8-K filing from Dexcom, Inc. on January 8, 2024, is a routine administrative update, primarily confirming its status as a publicly traded company on the Na